PULMOPHARMA ApS: Financial statements 2018
CVR: 36428023
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
PULMOPHARMA ApS (CVR 36428023) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK -292,381 and a net result of DKK -223,907 compared with DKK -123,491 the year before. Equity in the 2018 report amounted to DKK -350,318.
- Gross Profit
- DKK -292,381
- Profit/Loss
- DKK -223,907
- Equity
- DKK -350,318
- Total Assets
- DKK 75,148
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | - | -292 t. | -224 t. | -350 t. | - |
| 2017 | - | -120 t. | -123 t. | -126 t. | - |
| 2016 | - | 0 | 0 | -3 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
PULMOPHARMA ApS has published its annual report for 2017. Gross profit came to DKK -120,467, and the net result was DKK -123,491.
As of January 4, 2018, Per Bendix Jeppesen has stepped down as director of PULMOPHARMA ApS.
As of January 4, 2018, Torben Ballegaard Sørensen has stepped down as director of PULMOPHARMA ApS.
About PULMOPHARMA ApS
PULMOPHARMA ApS is a Danish company of the type Anpartsselskab based in Ebeltoft, founded in 2014. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Dan Mønster Nielsen. The board consists of Torben Ballegaard Sørensen (chair), Dan Mønster Nielsen, Per Bendix Jeppesen and Peter Frithjof Bang. The company's owners include PETER BANG HOLDING ApS, LARS NYENSTAD ApS and BENDIX-HOLDING ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -49,353 and a net result of DKK -49,353 compared with DKK -20,499 the year before. Equity in the 2025 report amounted to DKK 11,436,934.